1.
Gu C, Cheng H, Yang H, Bian Y, Wang Y, Zhang Y, Pisano M, Hu G, Yang Y. MK2 is a therapeutic target for high-risk multiple myeloma. Haematologica [Internet]. 2021Jun.1 [cited 2026Nov.17];106(6):1774-7. Available from: https://haematologica.org/article/view/9550